Description
GHRP-6 is a synthetic hexapeptide growth hormone secretagogue — the original first-generation GHRP from which the broader peptide class takes its name. It activates GHSR-1a through Gq/11 protein coupling and intracellular calcium mobilization to stimulate GH release from anterior pituitary somatotrophs. Its defining research characteristic is its broad GHSR-1a engagement profile: GHRP-6 activates the full pharmacological footprint of ghrelin receptor stimulation, including potent orexigenic signaling through hypothalamic NPY/AgRP pathways and significant ACTH and cortisol co-stimulation alongside GH release. Researchers studying the full scope of ghrelin receptor biology — rather than isolated GH pulse dynamics — select GHRP-6 specifically because of this broad receptor engagement, not despite it.
Key Characteristics
- Potent orexigenic signaling is a defining pharmacological feature — GHRP-6 activates hypothalamic NPY and AgRP pathways downstream of GHSR-1a, producing food intake stimulation that researchers studying appetite regulation and energy homeostasis signaling use as a primary experimental variable
- Broader GHSR-1a downstream engagement than GHRP-2 — where GHRP-2 offers higher receptor selectivity and a cleaner GH pulse profile, GHRP-6’s less selective receptor footprint makes it the appropriate tool when the research question involves the full breadth of ghrelin pathway activity rather than isolated somatotroph stimulation
- CD36 scavenger receptor interaction — like Hexarelin, GHRP-6 has documented CD36 activity, which connects it to cardiac and cytoprotective signaling research contexts that extend beyond its GH secretagogue properties
- ACTH and cortisol co-stimulation is pronounced relative to other GHRPs — this off-target axis activation makes GHRP-6 less appropriate for GH-focused studies where glucocorticoid confounds would complicate interpretation, but relevant in research examining interactions between the GH axis and the hypothalamic-pituitary-adrenal axis
- First-generation GHRP predating the cloning of GHSR-1a — the historical position of GHRP-6 in the secretagogue literature means it appears in foundational GH research studies as a reference compound, giving it a longer and more extensive citation record than newer, more selective GHRPs
Handling and Storage
Store as lyophilized powder under refrigeration, away from heat, moisture, and light. Reconstitute immediately before use and avoid repeated freeze-thaw cycles to preserve GHSR-1a binding activity.
FAQs
What is GHRP-6?
GHRP-6 is the original first-generation synthetic hexapeptide growth hormone secretagogue, activating GHSR-1a through Gq/11-mediated intracellular calcium signaling to stimulate GH release from anterior pituitary somatotrophs. It is studied for its broad ghrelin receptor pharmacology, including potent orexigenic signaling through hypothalamic NPY/AgRP pathways and ACTH/cortisol co-stimulation, for which newer, more selective GHRPs were designed to reduce.
Why would a researcher choose GHRP-6 over more selective GHRPs?
More selective GHRPs like Ipamorelin and GHRP-2 were developed specifically to isolate GH release from the broader ghrelin receptor pharmacology that GHRP-6 produces. Researchers choose GHRP-6 when that broader pharmacology is the research target — when the study is designed to examine orexigenic signaling, NPY/AgRP pathway activity, or the interaction between ghrelin receptor stimulation and hypothalamic-pituitary-adrenal axis function. The “confounds” that make GHRP-6 less suitable for pure GH studies are the experimental variables in appetite and stress axis research.
How does GHRP-6’s CD36 interaction relate to its research applications?
CD36 is a scavenger receptor expressed in cardiac, adipose, and immune cell populations. GHRP-6’s documented CD36 activity — shared with Hexarelin but absent from more selective GHRPs — connects it to research models examining cytoprotective and cardioprotective signaling independent of its GH secretagogue properties. Researchers studying GHSR-1a biology specifically use Ipamorelin or GHRP-2; those examining how ghrelin receptor agonism interacts with peripheral scavenger receptor biology include GHRP-6 in designs where CD36-mediated signaling is a relevant variable.
